Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis
NCT01869465 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1277
Last updated 2013-06-05
Summary
Previous research undertaken among adults in high endemic districts of Busia, Adjumani, Moyo and Nebbi reported unwillingness to take preventive treatment. A particular study conducted in primary schools of Jinja district showed that only 30% of school children took praziquantel during the 2011 Mass Drug Administration (MDA). Fear of side effects of praziquantel, lack of knowledge about schistosomiasis transmission and prevention and lack of teacher support were some of the major factors associated with the low uptake. Similar reasons for non-uptake have been reported elsewhere. Thus, measures are needed to increase uptake of Mass Drug Administration (MDA) in Uganda. There is no doubt that health education facilitates a better understanding of the obvious risks to health, including the knowledge of preventing parasitic infections among primary school children. Better compliance to treatment for schistosomiasis among school children can be achieved through implementing carefully designed programs involving face to face education methods. Increasing knowledge about schistosomiasis transmission and prevention and implementing measures to mitigate the side effects attributable to praziquantel, such as providing a snack prior to drug administration may improve uptake of the drug among school children.
Hypothesis- Provision of a pre-treatment snack is effective in improving uptake of preventive treatment for intestinal schistosomiasis among primary school children.
Conditions
- Schistosomiasis
Interventions
- OTHER
-
Pre-treatment snack
The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
- BEHAVIORAL
-
Education arm
In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
Sponsors & Collaborators
-
University of Copenhagen
collaborator OTHER -
Makerere University
lead OTHER
Principal Investigators
-
Simon Muhumuza, MBChB, MPH · Makerere University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 10 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2013-06-30
- Completion
- 2013-06-30
Countries
- Uganda
Study Locations
More Related Trials
-
Health Benefits of Repeated Treatment in Pediatric Schistosomiasis
NCT01424410 ·Status: COMPLETED
-
Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment
NCT02495909 ·Status: COMPLETED
-
Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?
NCT02612896 ·Status: COMPLETED ·Phase: NA
-
Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis
NCT02734186 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology
NCT02878564 ·Status: COMPLETED ·Phase: PHASE4
-
Schistosoma Mansoni in Mwanza Region, Tanzania
NCT02162875 ·Status: COMPLETED ·Phase: NA
-
Adoption of L-PZQ for Schistosomiasis by Endemic Counties - Social Science Research Study
NCT05350462 ·Status: ACTIVE_NOT_RECRUITING
-
Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana
NCT00463931 ·Status: COMPLETED
-
Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
NCT06335160 ·Status: RECRUITING ·Phase: NA
-
Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis
NCT06376396 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Evaluation of a Comprehensive School Health Programme in Zambia
NCT06560853 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia
NCT00276224 ·Status: COMPLETED ·Phase: NA
-
Education Intervention to Reduce Helminth Infections and Absenteeism in Grade 5 School-children
NCT01085799 ·Status: COMPLETED ·Phase: NA
-
Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania
NCT00347113 ·Status: COMPLETED ·Phase: NA
-
Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
NCT00001645 ·Status: RECRUITING
-
Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni
NCT04679831 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Health Education Model Led by Community Health Volunteers.
NCT06312462 ·Status: COMPLETED ·Phase: NA
-
Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs
NCT04177654 ·Status: COMPLETED
-
Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment
NCT00414479 ·Status: COMPLETED
-
Schistosoma Haematobium Infections and Praziquantel
NCT01558336 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of an AI-DP for STH Deworming Programs: a Study Protocol
NCT06055530 ·Status: UNKNOWN
-
Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa
NCT01154907 ·Status: UNKNOWN
-
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil
NCT00403611 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
NCT01541631 ·Status: UNKNOWN ·Phase: NA
-
Epidemiology and Control of Mansonella Perstans Infection in Uganda
NCT00215280 ·Status: COMPLETED ·Phase: NA